Home / News / RT40 Retatrutide Peptide: Latest Research Progress & Literature Reference for Metabolic Research | CAS 2381089-83-2

RT40 Retatrutide Peptide: Latest Research Progress & Literature Reference for Metabolic Research | CAS 2381089-83-2

Views: 0     Author: Site Editor     Publish Time: 2026-10-16      Origin: Site

Inquire

facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button

RT40 Retatrutide Peptide: Latest Research Progress & Literature Reference for Metabolic Research

RT40-Retatrutide-peptide-bulk-lab-packaging-supplier

RT40 is our catalog number for Retatrutide, also known as LY3437943, a breakthrough synthetic triple receptor agonist peptide targeting GLP‑1R, GIPR and GCGR. Since its first publication in Cell Metabolism in 2022, this peptide has become one of the most widely studied tool compounds for endocrine and metabolic pathway research in academic labs and biotech institutes worldwide.


1. Core Research Mechanism


Different from dual agonists such as tirzepatide, Retatrutide can simultaneously activate three hormone receptors.


• GLP‑1R: Regulates glucose-dependent insulin release and satiety signaling


• GIPR: Enhances insulin response and participates in adipose tissue remodeling


• GCGR: Promotes hepatic energy expenditure and fatty acid oxidation


This triple activation mechanism makes RT40 a valuable research tool for exploring cross-talk between multiple incretin hormone pathways, adipocyte fibrosis, lipid metabolism and body composition regulation.


2. Latest Published Literature & TRIUMPH Program Research Update


The TRIUMPH series phase 3 trials are the most cited recent research for Retatrutide, with key findings published in The New England Journal of Medicine and The Lancet in 2026.


1. TRIUMPH‑1 (Obesity population research)

Up to 28.3% average body weight reduction after 80 weeks of observation; 45.3% subjects achieved ≥30% weight loss. This dataset is widely quoted for studying long-term metabolic adaptation under triple-agonist stimulation.


2. TRIUMPH‑2 (Type 2 diabetes related research)

Research focused on glycemic control and lipid profile changes in overweight diabetic populations, providing reference data for glucose homeostasis study.


3. TRIUMPH‑4 (Obesity combined with knee osteoarthritis model)

The study explored the connection between metabolic improvement and joint inflammation relief, expanding the research boundary of multi-system metabolic regulation.


Additional preclinical multi-omics research published in 2026 revealed that Retatrutide can remodel dysfunctional white adipose tissue, suppress lipogenesis and inflammatory fibrosis, and restore mitochondrial oxidative function. This paper provides new molecular evidence for researchers studying adipose tissue metabolism.

Main cited references for laboratory literature review:

1. Coskun T, et al. Discovery and preclinical characterization of LY3437943 (Retatrutide). Cell Metabolism, 2022.


2. Jastreboff AM, et al. Retatrutide for obesity. N Engl J Med, 2026.


3. Bellido V, et al. Retatrutide in adults with obesity and type 2 diabetes. The Lancet, 2026.


3. RT40 Product Information for Laboratory Research


Our RT40 Retatrutide peptide is manufactured via solid-phase peptide synthesis (SPPS), purified with preparative HPLC.


• Catalog No: RT40


• CAS: 2381089-83-2


• Purity: ≥99% HPLC


• Form: White to off-white lyophilized powder


• Storage: -20°C sealed, dry and away from light


• Grade: Research Grade Only


Every batch comes with complete testing documents: COA, HPLC chromatogram and MS spectrum to confirm molecular identity and purity. Consistent batch quality reduces experimental variation for your lab projects.


4. Available Services for Global Research Buyers


✅ Free sample for preliminary quality verification before bulk purchase

✅ Custom peptide synthesis and custom vial packaging support

✅ Low-temperature moisture-proof packing for safe worldwide shipping

✅ Flexible MOQ, fast production lead time for lab & bulk procurement


Important Disclaimer


RT40 Retatrutide peptide is FOR LABORATORY RESEARCH USE ONLY.

Not for human or veterinary injection, clinical treatment, food or cosmetic application. All trial data cited in this article comes from public scientific literature, only for biochemical research reference. End users are responsible for proper storage and laboratory handling.



QUICK LINKS

PRODUCTS

CONTACT
  400‑869‑432
Copyright © Rchemsell. All Rights Reserved. Website: www.rchemsell.com. Sitemap  | Privacy Policy | Terms of Service | Return & Refund Policy